Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim

Our aim was to compare the efficacy and safety of two recently developed biosimilars of pegfilgrastim, a pegylated form of the recombinant human granulocyte‐colony stimulating factor (G‐CSF) analog filgrastim with those of the reference pegfilgrastim. We retrospectively analyzed data from patients d...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2020-09, Vol.9 (17), p.6102-6110
Main Authors: Kang, Ka‐Won, Lee, Byung‐Hyun, Jeon, Min Ji, Yu, Eun Sang, Kim, Dae Sik, Lee, Se Ryeon, Sung, Hwa Jung, Choi, Chul Won, Park, Yong, Kim, Byung Soo
Format: Article
Language:English
Subjects:
Biological products
biosimilar
Bone marrow
Chemotherapy
Clinical Cancer Research
Colony-stimulating factor
Drug dosages
febrile neutropenia
Granulocytes
Leukocytes (granulocytic)
Lymphoma
Neutropenia
Neutrophils
Original Research
Patients
pegylated granulocyte‐colony stimulating agent
Prophylaxis
Safety
Survival analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Our aim was to compare the efficacy and safety of two recently developed biosimilars of pegfilgrastim, a pegylated form of the recombinant human granulocyte‐colony stimulating factor (G‐CSF) analog filgrastim with those of the reference pegfilgrastim. We retrospectively analyzed data from patients diagnosed with diffuse large B‐cell lymphoma (DLBCL) who were treated with first‐line R‐CHOP chemotherapy and received pegylated G‐CSF for primary prophylaxis. The following pegylated G‐CSFs were analyzed in this study: reference pegfilgrastim (Neulasta®) and two of its biosimilars (tripegfilgrastim; Dulastin® and pegteograstim; Neulapeg®). In total, 296 patients were enrolled. The number of patients with at least one episode of neutropenia during R‐CHOP chemotherapy was the lowest in the reference cohort (pegfilgrastim: 127 of 193 patients, 65.8%; tripegfilgrastim: 64 of 69 patients, 92.8%; pegteograstim: 28 of 34 patients, 82.4%, P 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.3261